← Eichor
Condition: Myeloproliferative Disorders Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myeloproliferative Disorders

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Pat
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07128381Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
NA · 1 location(s) · Peking University People's Hospital · NCT07588594TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Phase 1 · 2 location(s) · Shenzhen TargetRx Co., Ltd. · NCT06088888MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Molecular Biology of Polycythemia and Thrombocytosis
Phase N/A · 1 location(s) · University of Utah · NCT00722527I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
NA · 3 location(s) · Massachusetts General Hospital · NCT05842603ARMSTRONG - Air entRainMent vS sTandard tReatment in nOn-expandable luNG
NA · 1 location(s) · Cambridge University Hospitals NHS Foundation Trust · NCT06959719Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT04708054Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 2 · 1 location(s) · University of Manitoba · NCT06599762Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Phase 2 · 24 location(s) · Novartis Pharmaceuticals · NCT07354074A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK I
Phase 1/Phase 2 · 12 location(s) · iOnctura · NCT06887803MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
NA · 3 location(s) · University of Miami · NCT05745285Blood Viscosity in Polycythemia Patients
Phase N/A · 1 location(s) · Hospices Civils de Lyon · NCT06421025A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Phase 1 · 5 location(s) · Prelude Therapeutics · NCT07469891A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Phase 1/Phase 2 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT06773195Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplas
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07228624A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and
Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06566742Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Phase 1 · 1 location(s) · University of Virginia · NCT07270978Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991Momelotinib During and After HCT in Myelofibrosis
Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT07104799A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
Phase 2 · 1 location(s) · Korean Society of Hematology · NCT06368414Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyc
Phase 1 · 2 location(s) · University of Kansas Medical Center · NCT03533816Pacritinib in CMML
Phase 1/Phase 2 · 1 location(s) · Douglas Tremblay · NCT06159491Asciminib RMP Study
Phase N/A · 17 location(s) · Novartis Pharmaceuticals · NCT05943522Vitamin A and D Supplementation in Allogeneic HCT
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT06508099Caris Chromoseq Data Collection
Phase N/A · 1 location(s) · Caris Science, Inc. · NCT07680868Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.